Sight Sciences, Inc.

As of September 12, 2025, Sight Sciences, Inc. is in a mildly bearish trend, with weekly indicators signaling bearishness despite some daily moving averages being mildly bullish, and the stock has underperformed the S&P 500 by -43.75% compared to its 17.14% return over the past year.

As of June 17, 2025, the market trend is neutral with mixed signals, showing a sideways movement characterized by bullish weekly indicators and mildly bearish monthly indicators, indicating a consolidation phase rather than a clear trend.

Sight Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $18 million and a net loss of $14 million as of March 2025. The company has a market cap of $208.36 million and does not pay dividends.

As of Jun 18, Sight Sciences, Inc. has a market capitalization of 208.36 million and reported net sales of 78.11 million with a net profit of -49.40 million over the latest four quarters. Shareholder's funds are at 87.52 million, and total assets are 142.84 million as of Dec 24.